AUSTRALIA'S Griffith University has entered into a $135 million commercial partnership with Gene Company to further develop a new drug treatment for SARS-CoV-2, the virus responsible for COVID-19.
Prof Kevin Morris from Griffith's School of Medical Science said the utility of this technology is paradigm shifting and Gene Company, recently established in Queensland, will lead the development of the first-in-class RNA nanoparticle drug candidates in Australia.
"This treatment will work differently than other anti-virals currently available as it directly targets the viral RNA and cuts it up, rendering it deceased," Morris shared.
The above article was sent to subscribers in Pharmacy Daily's issue from 02 Aug 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 02 Aug 23
